A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: David Gil-Ortega |
| Publication date | April 21, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |